Alnylam Pharmaceuticals Q3 2025 Earnings Preview

* Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) is scheduled to announce Q3 earnings results on Thursday, October 30th, before market open.
* The consensus EPS Estimate is $1.75 [https://seekingalpha.com/symbol/ALNY/earnings/estimates] (vs. -$0.50 in Q3/2024) and the consensus revenue estimate is $974.12M (+94.5% Y/Y).
* Over the last 2 years, ALNY has beaten EPS estimates [https://seekingalpha.com/symbol/ALNY/earnings/eps-surprise-summary] 63% of the time and has beaten revenue estimates 63% of the time.
* Over the last 3 months, EPS estimates have seen 10 upward revisions [https://seekingalpha.com/symbol/ALNY/earnings/revisions] and 0 downward. Revenue estimates have seen 19 upward revisions and 0 downward.

MORE ON ALNYLAM PHARMACEUTICALS

* Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript [https://seekingalpha.com/article/4825228-alnylam-pharmaceuticals-inc-alny-presents-at-bernstein-insights-healthcare-leaders-and]
* Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4821674-alnylam-pharmaceuticals-inc-alny-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript [https://seekingalpha.com/article/4819156-alnylam-pharmaceuticals-inc-alny-presents-at-citis-biopharma-back-to-school-conference]
* Alnylam yanks Amvuttra TV ad following FDA letter - report [https://seekingalpha.com/news/4501489-alnylam-yanks-amvuttra-tv-ad-following-fda-letter]
* Goldman's 48 potential M&A candidates [https://seekingalpha.com/news/4499689-goldmans-48-potential-ma-candidates]